Protagonist Therapeutics, Inc. (PTGX) Insider David Y. Liu Sells 7,000 Shares
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $16.97, for a total value of $118,790.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of Protagonist Therapeutics, Inc. (NASDAQ PTGX) traded down $0.39 during midday trading on Wednesday, hitting $16.57. The stock had a trading volume of 108,200 shares, compared to its average volume of 83,662. Protagonist Therapeutics, Inc. has a 1-year low of $8.00 and a 1-year high of $26.36.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Monday, November 6th. The company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.40. The firm had revenue of $8.78 million during the quarter. sell-side analysts predict that Protagonist Therapeutics, Inc. will post -3.66 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its position in Protagonist Therapeutics by 60.8% during the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock valued at $169,000 after purchasing an additional 3,617 shares during the period. First Manhattan Co. acquired a new position in Protagonist Therapeutics during the 3rd quarter valued at approximately $293,000. California State Teachers Retirement System boosted its position in Protagonist Therapeutics by 8.5% during the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after purchasing an additional 1,300 shares during the period. State Street Corp boosted its position in Protagonist Therapeutics by 20.9% during the 2nd quarter. State Street Corp now owns 112,474 shares of the company’s stock valued at $1,270,000 after purchasing an additional 19,411 shares during the period. Finally, Senzar Asset Management LLC acquired a new position in Protagonist Therapeutics during the 2nd quarter valued at approximately $3,094,000. Institutional investors and hedge funds own 39.73% of the company’s stock.
A number of equities research analysts have recently weighed in on PTGX shares. BTIG Research started coverage on Protagonist Therapeutics in a report on Friday, July 21st. They issued a “buy” rating and a $36.00 price target for the company. Zacks Investment Research upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Finally, BMO Capital Markets lowered their price target on Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, October 19th.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Stock Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related stocks with our FREE daily email newsletter.